Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis

Recent clinical trials have demonstrated that anti‐PD‐1 blocking antibodies showed remarkable clinical efficacy in a subset of non‐small cell lung cancer (NSCLC) patients. Clinical trials usually exclude patients with renal dysfunction who are receiving hemodialysis (HD). Therefore, it is unclear wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Osa, Akio, Uenami, Takeshi, Naito, Yujiro, Hirata, Haruhiko, Koyama, Shohei, Takimoto, Takayuki, Shiroyama, Takayuki, Futami, Shinji, Nakatsubo, Saeko, Sawa, Nobuhiko, Yano, Yukihiro, Nagatomo, Izumi, Takeda, Yoshito, Mori, Masahide, Kida, Hiroshi, Kumanogoh, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825915/
https://www.ncbi.nlm.nih.gov/pubmed/31520515
http://dx.doi.org/10.1111/1759-7714.13197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825915/
https://www.ncbi.nlm.nih.gov/pubmed/31520515
http://dx.doi.org/10.1111/1759-7714.13197

Ejemplares similares